It also lists adverse events for which a relationship to the administered drug is suspected but not thoroughly verified (important potential risks) and identifies the information considered insufficient (important missing information) for predicting the post-marketing safety of the drug. RMP lists already confirmed ADRs (important identified risks). Sharing the published information among medical professionals is meant to ensure further enhancements of post-marketing safety measures. The RMP aims that the risks of drugs are evaluated at regular intervals or in response to the progress of post-marketing surveillance and a set of pharmacovigilance activities to minimize the risks of drugs. ![]() ![]() The RMP is a document which shows the consistent risk management of drug from the development phase to the post-marketing phase. In order to ensure the safety of drugs, it is important to assess measures for appropriate management of the risks of drugs at any time from the development phase to the regulatory review and the post-marketing phase.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |